Best Stocks Under $5 Right Now → The asset beating inflation by 4x (From Colonial Metals) (Ad) Written by MarketBeat StaffUpdated July 19, 2022What Are Penny Stocks?Should Investors Buy Stocks Under $5?What Are the Rewards of Buying Stocks Under $5?What Are the Risks of Buying Stocks Under $5?How to Trade Stocks Under $5?What Are the Best Stocks Under $5?Like any group of stocks, penny stocks require discerning between price and value There is a primal attraction to stocks priced under $5. These stocks are also known as penny stocks. Some purists will suggest that penny stocks have to trade for less than $1. However, in recent years, investors generally accept the definition that any stock that consistently trades below $5 fits into the category of penny stocks. In this article, we’ll explain why stocks under $5 are considered penny stocks and whether investors should invest in penny stocks at all. We’ll also outline some of the risks and the rewards of buying stocks under $5. And we’ll provide some tips for successfully trading these stocks. What Are Penny Stocks? As mentioned above, penny stocks are stocks that trade for $5 or less. This definition means there are many options for investors including dollar stocks, penny stocks, and stocks that sell for fractions of one penny. One stereotype about penny stocks is that every company is a startup that is in a risky market sector. However, there are many established businesses trading on standard exchanges that trade for less than $5 per share. When these companies appear on major exchanges, they are viewed as carrying less risk because they have to meet regulatory requirements that keep their accounting transparent. That being said, penny stocks are usually small-cap companies (i.e. those with a market capitalization of less than $2 billion) that are either new to the market or undervalued and not recognized by investors. There tend to be fewer shares of these stocks available, meaning there is usually a wider spread between bids and asking prices. And because penny stocks are generally considered to be speculative investments, they carry a certain element of risk. But it’s this risk that provides the opportunity for investors to make significant gains. Should Investors Buy Stocks Under $5? A broader question might be, “Should you buy stocks at all?” The answer to both questions is the same: It depends. You should not buy stocks if you don’t have a discriminating sense of how to invest money, or if you don’t have guidance around the topic from someone who does. With the right knowledge, stocks are an excellent investment, and according to some estimates, far more sound than real estate. Yes, stock prices do fluctuate (sometimes wildly), but over the last several decades, they have outperformed real estate in some regards. And investors who know what they’re doing with stocks can make huge gains, build enormous wealth, and create exponential financial success. Stocks under $5, in particular, present an incredible opportunity to make huge gains. It all comes down to research. You never want to sink all of your investment cash into just one basket. Estimates vary on the exact percentage, but most experts agree that the majority of your portfolio should be invested in solid, stable companies. That said, stocks under $5 can be a good place to do a little value investing and give some growth to your cash. It’s important to keep in mind that there are many trading strategies in relation to the stock market, and investing in undervalued, up-and-coming companies is only one strategy. For example, some investors prefer to focus on stocks that pay out dividends, where each share pays out dividend payments of company profit—and a large number of shares creates a solid cash flow. Other investors like to buy shares in specific industries, like tech stocks, or they may choose to ride the market as they engage in the ups and downs of day trading, flipping stocks for profit. Whichever stock trading strategy you prefer, penny stocks can be some of the best growth stocks for their undervalued cost—if you trade the right way. What Are the Rewards of Buying Stocks Under $5? As mentioned, penny stocks present huge opportunities for growth. Take True Religion as an example—an apparel company based in Vancouver, Canada. This designer-jeans outfit was trading for $0.67 per share in July of 2004. Just nine years later, TowerBrook Capital Partners acquired the company and paid $32 for every share...a whopping 4676% profit. Can you think of any “normal stocks” that offered investors the same gains? They’re few and far between (though they do exist). These are the types of profit margins that traders dream of earning. Another advantage of penny stocks is that they can be an easy way for small-time investors to enter the market. You don’t necessarily have to sink everything into some sort of risky biotech company. There are plenty of brand-name companies that are trading at under $5. Purchasing shares of these recognized businesses could be your chance to enter the stock market in an affordable way—and cash out big if things work out. It’s not just about price, but about volume: A $500 investment might only buy you 5-10 shares of a recognizable blue-chip stock or it could buy you 100+ shares of a stock priced at $5 and below. If that company grows and becomes a mid-cap stock, you’ll see a lot more profit than you would have by investing in a more “normal” stock. For that very same reason, penny stocks may allow you to diversify your holdings to a greater extent, with less money (if you want to eschew mutual funds and pick stocks yourself). With just $100 in the market, you could buy ten shares of stock in ten different industries. What Are the Risks of Buying Stocks Under $5? Many stocks under $5 are companies that may be startups or riskier business ventures. One of the biggest examples is biotech, an industry with larger startup costs and huge risks for investors. A startup company may discover the cure for cancer, in which case, you can cash out as a billionaire. Or, they may not, and they’ll take all your money with them when they fold. Another disadvantage to stocks under $5 is that they may be stocks of a company that’s about to go bankrupt. They could be desperately selling shares of stock to raise money, or to help their executives bail out with a parachute built from your investment. Newly formed startups may also be on the verge of bankruptcy, and because of their lack of established history, no one may even know. Occasionally penny stocks will be part of a “pump and dump” scam, where investors build excitement over a particular stock to drive up the price. They may “leak” information that a startup energy company struck gold or put forth an imaginative but enticing earnings estimate for the next quarter. As the stock value climbs out of control (far beyond the actual value of the market cap), hoodwinked investors pour their dollars into the company. Then it crashes, and the only ones who benefit are the scammers who bought into the stock before they made it popular. Another more prosaic risk of stocks under $5 is that they may just not go anywhere, hovering under $5 for years on end. While this is certainly better than losing all your money, it’s not so conducive to portfolio growth. Yet another disadvantage to stocks under $5 is their low trading volume. They can be harder to unload if you need to, because you may not find a willing buyer. Moreover, many penny stocks of younger upstart companies will most likely not pay out dividends. You are only purchasing the stock to leverage a change in its price—or hoping that in the future they will play into your dividend investing strategy. As you can see, there are some risks and volatility associated with stocks under $5. However, it once again all comes down to playing it smart and doing your research. There are plenty of resources which will tell you about the most volatile stocks, along with providing stats to gauge their future possibilities. If you have a good head for what’s going on, you won’t fall for scams or pour all your money into a pipe dream. The best traders know which stocks to watch; they understand the ins and outs of dividend yield and market capitalization—and can leverage these stats into higher amounts of revenue. There’s no secret to what they’re doing. They’re actively learning and keeping their eyes on the best times to buy stocks at 52 week low points. They know when to hold their assets, and when to sell them. How to Trade Stocks Under $5? Some stocks under $5 are traded on the New York Stock Exchange and NASDAQ. However, most stocks under $5 trade through over the counter transactions (OTC). Everything about these OTC transactions is done electronically through the OTC Bulletin Board (OTCBB). Companies that are traded on the OTCBB must still meet requirements from the SEC and FINRA. However, these companies don’t meet the requirements for trading on a larger market. There are still more stocks under $5 that don’t even meet the requirements to be traded on the OTCBB. These stocks can be found on a listing service called Pink Sheets (so named because the stocks were once listed on pink sheets of paper). These companies are too small to be listed on a national exchange, or may not wish to make their accounting statements public—which means they don’t have to file with the SEC, and can’t be listed on a publicly-traded market. As you might expect, these Pink Sheet stocks can carry significant risks. They can be difficult to analyze because of the lack of transparency around their business; investors should use caution and due diligence when purchasing them. What Are the Best Stocks Under $5? Now that we’ve reviewed the pros and cons of stocks under $5 and explained how they work, let’s address the question that every investor wants to know: how do I actualize this information? It can be hard to find good stocks under $5, particularly in bull markets. This is a time when stocks frequently hit new all-time highs, and the price-to-earnings ratios of most S&P 500 companies make purchasing shares look like an expensive proposition. For these and other reasons, many investors have trouble finding low-priced stocks that haven't already appreciated greatly. In more normal markets, a typical S&P 500 company trades at about fifteen times their earnings. However, value investing opportunities do exist—if you're looking in the right places. Putting together a list of the best stocks under $5 requires investors to look at smaller and riskier companies in sectors that are either undiscovered or unrecognized by the market as a whole. When looking at cheap stocks to buy, some of them may not look especially attractive today, but long-term investors will recognize profit if they are willing to exercise patience and hold onto shares of these companies through multiple economic cycles. Some of these companies are solid investing ideas because they are small. As a result, they’re considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unrecognized or untested areas of the market. You may find even find crypto stocks, marijuana stocks, and bitcoin stocks on this list. Others have been beaten up by Mr. Market after a long period of slowing profits but are now actively trying to turn around their business and bounce back. This low-priced list of stocks showcases a lot of different industries, but these picks all carry two common characteristics: They all have a super-low share price of $5.00 or less, and they all consistently receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio. Top Headlines and OffersView All HeadlinesTop 4 Fastest Growing S&P 500 Dividends: Buy, Sell, or Hold?By Thomas Hughes | June 12, 2024View Top 4 Fastest Growing S&P 500 Dividends: Buy, Sell, or Hold?Stock market today: Wall Street hangs around its records after European stocks slumpBy The Associated Press | June 14, 2024View Stock market today: Wall Street hangs around its records after European stocks slumpMust-See: Elon’s New Invention is Absolutely InsaneFrom InvestorPlace(Ad)View Must-See: Elon’s New Invention is Absolutely Insane3 Stocks That Plummeted After the Post-Fed Speech CrashBy Gabriel Osorio-Mazilli | June 14, 2024View 3 Stocks That Plummeted After the Post-Fed Speech CrashHere's Why Analysts Boosted Walmart Stock's ValuationBy Gabriel Osorio-Mazilli | June 13, 2024View Here's Why Analysts Boosted Walmart Stock's ValuationBitcoin Breakout Looms: Which Crypto Stocks Will Ride the Wave?By Ryan Hasson | June 14, 2024View Bitcoin Breakout Looms: Which Crypto Stocks Will Ride the Wave?The asset beating inflation by 4xFrom Colonial Metals(Ad)View The asset beating inflation by 4xWhat is a Dividend Trap? Here's What You Should KnowBy Dan Schmidt | June 14, 2024View What is a Dividend Trap? Here's What You Should Know3 High-Yield Dividend Stocks for Income Now and Growth LaterBy Chris Markoch | June 14, 2024View 3 High-Yield Dividend Stocks for Income Now and Growth LaterTop 5 High-Performance Cryptocurrency ETFs to WatchBy Jeffrey Neal Johnson | June 14, 2024View Top 5 High-Performance Cryptocurrency ETFs to WatchBeyond GME: Top 3 WallStreetBets Stocks Better Than GameStopBy Chris Markoch | June 12, 2024View Beyond GME: Top 3 WallStreetBets Stocks Better Than GameStopAdobe Stock: It’s Not Too Late To Buy The DipBy Thomas Hughes | June 14, 2024View Adobe Stock: It’s Not Too Late To Buy The Dip Show: Stocks Under $0.50 Stocks Under $1.00 Stocks Under $2.00 Stocks Under $5.00 Stocks Under $10.00 Stocks Under $20.00 Stocks Under $30.00 Stocks Under $50.00 Stocks On Sale #1 - Ocuphire PharmaNASDAQ:OCUPStock Price: $1.53 (-$0.15)P/E Ratio: -3.12Market Cap: $39.66 millionAverage Trading Volume: 193,827 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $18.75 (1,125.5% Upside)Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan. Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. #2 - PMV PharmaceuticalsNASDAQ:PMVPStock Price: $1.61 (-$0.04)P/E Ratio: -1.21Market Cap: $82.82 millionAverage Trading Volume: 518,177 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.75 (257.1% Upside)PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.#3 - Clean Energy FuelsNASDAQ:CLNEStock Price: $2.51 (-$0.06)P/E Ratio: -7.17Market Cap: $560.38 millionAverage Trading Volume: 1.65 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.60 (123.1% Upside)Clean Energy Fuels Corp. provides natural gas as alternative fuels for vehicle fleets and related fueling solutions in the United States and Canada. It supplies renewable natural gas (RNG), compressed natural gas (CNG), and liquefied natural gas (LNG) for medium and heavy-duty vehicles; and offers operation and maintenance services for public and private vehicle fleet customer stations. The company also designs, builds, operates, and maintains vehicle fueling stations; and sells and services compressors and other equipment that are used in RNG production and fueling stations. In addition, it transports and sells CNG, RNG, and LNG through virtual natural gas pipelines and interconnects; sells U.S. federal, state, and local government credits, such as RNG as a vehicle fuel, including Renewable Identification Numbers and Low Carbon Fuel Standards credits; and obtains federal, state, and local credits, grants, and incentives. Further, the company focuses on developing, owning, and operating dairy and other livestock waste RNG projects. It serves heavy-duty trucking, airports, refuse, public transit, industrial, and institutional energy users, as well as government fleets. Clean Energy Fuels Corp. was incorporated in 2001 and is headquartered in Newport Beach, California.#4 - Aquestive TherapeuticsNASDAQ:AQSTStock Price: $2.68 (-$0.05)P/E Ratio: -6.38Market Cap: $243.99 millionAverage Trading Volume: 1.98 million sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.00 (198.5% Upside)Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.#5 - Zura BioNASDAQ:ZURAStock Price: $3.38 (-$0.35)Market Cap: $147.33 millionAverage Trading Volume: 250,687 sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $19.80 (485.8% Upside)Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.#6 - Rani TherapeuticsNASDAQ:RANIStock Price: $3.89 (+$0.08)P/E Ratio: -3.02Market Cap: $196.13 millionAverage Trading Volume: 116,775 sharesConsensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $12.29 (215.8% Upside)Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.[Urgent] Protect your money before November (Ad)Those who listened to his warnings could have kept their money safe and even made substantial profits during each crisis. In fact, the Wall Street Journal reported that his work was more accurate … and more profitable than that of … Deutsche Bank … Merrill Lynch … JPMorgan Chase … Goldman Sachs … and every other firm reviewed.Click here to watch now.#7 - Gold RoyaltyNYSEAMERICAN:GROYStock Price: $1.39 (-$0.04)P/E Ratio: -8.18Market Cap: $202.55 millionAverage Trading Volume: 841,479 sharesDividend Yield: 0.61%<Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.27 (135.3% Upside)Gold Royalty Corp., a precious metals-focused royalty company, provides financing solutions to the metals and mining industry. It focuses on acquiring royalties, streams, and similar interests at varying stages of the mine life cycle to build a portfolio offering near, medium, and longer-term returns for its investors. Gold Royalty Corp. was incorporated in 2020 and is headquartered in Vancouver, Canada.#8 - Sagimet BiosciencesNASDAQ:SGMTStock Price: $3.95 (-$0.27)Market Cap: $120.04 millionAverage Trading Volume: 1.17 million sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $39.20 (892.4% Upside)Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.#9 - Man GroupOTCMKTS:MNGPFStock Price: $3.26P/E Ratio: 111.30Average Trading Volume: 1,120 sharesDividend Yield: 3.50%<Consensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $128.50 (3,841.7% Upside)Man Group Limited is a publicly owned investment manager. The firm provides long-only and alternative investment management services worldwide. It offers a range of liquid investment products and solutions, which include quantitative, multi-manager and discretionary investment styles, and span across various asset classes, like equity, real estate, currency, credit, volatility, and commodities. The firm distributes its products and solutions directly to institutions and to private investors through a global network of intermediaries. Man Group Limited was founded in 1783 and is based in St. Helier, Jersey with an additional office in London, United Kingdom.#10 - Applied TherapeuticsNASDAQ:APLTStock Price: $4.50 (-$0.33)P/E Ratio: -2.45Market Cap: $514.22 millionAverage Trading Volume: 1.54 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $11.00 (144.4% Upside)Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.#11 - Nuvation BioNYSE:NUVBStock Price: $2.90 (-$0.04)P/E Ratio: -9.34Market Cap: $715.56 millionAverage Trading Volume: 1.24 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.60 (128.0% Upside)Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.[Urgent] Protect your money before November (Ad)Those who listened to his warnings could have kept their money safe and even made substantial profits during each crisis. In fact, the Wall Street Journal reported that his work was more accurate … and more profitable than that of … Deutsche Bank … Merrill Lynch … JPMorgan Chase … Goldman Sachs … and every other firm reviewed.Click here to watch now.#12 - TeraWulfNASDAQ:WULFStock Price: $4.51 (+$0.12)Market Cap: $1.50 billionAverage Trading Volume: 19.58 million sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.16 (-7.8% Upside)TeraWulf Inc., together with its subsidiaries, operates as a digital asset technology company in the United States. The company develops, owns, and operates bitcoin mining facilities in New York and Pennsylvania. It is also involved in the provision of miner hosting services to third-party entities. The company was founded in 2021 and is headquartered in Easton, Maryland.#13 - BlackSky TechnologyNYSE:BKSYStock Price: $0.93 (+$0.03)P/E Ratio: -2.45Market Cap: $136.74 millionAverage Trading Volume: 604,432 sharesConsensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.63 (181.9% Upside)BlackSky Technology Inc. provides geospatial intelligence, imagery and related data analytic products and services, and mission systems that include the development, integration, and operation of satellite and ground systems for government and commercial customers in North America, the Middle East, the Asia Pacific, and internationally. The company's Spectra software platform processes a range of observations from its satellite constellation and various external data sources, including imaging, radar and radio frequency satellites, environmental sensors, asset tracking sensors, Internet-of-Things (IoT) connected devices, internet-enabled narrative sources, and a variety of geotemporal data feeds. It offers a range of services related to object, change and anomaly detection, site monitoring, and enhanced analytics, which helps to detect key pattern of life changes in critical locations, including strategic locations and infrastructure comprising ports, airports, and construction sites; retail activity; commodities stockpiles; and other sites that contain critical commodities and supply chain inventory. In addition, the company develops and delivers satellites and payload systems; and provides professional and engineering services. Its products and services are used in national security, supply chain intelligence, crisis management, critical infrastructure monitoring, economic intelligence, and other applications. BlackSky Technology Inc. was incorporated in 2018 and is headquartered in Herndon, Virginia.#14 - PowerFleetNASDAQ:PWFLStock Price: $4.31 (-$0.14)P/E Ratio: -13.90Market Cap: $462.68 millionAverage Trading Volume: 621,937 sharesConsensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.43 (95.6% Upside)PowerFleet, Inc. provides wireless Internet-of-Things (IoT) asset management solutions in the United States, Israel, and internationally. The company offers real-time intelligence for organizations to capture IoT data from various types of assets with devices and sensors to increase efficiencies, and improve safety and security, as well as increase their profitability in easy-to-understand reports, dashboards, and real-time alerts; and application programming interfaces for additional integrations and development to boost other enterprise management systems and third-party applications. It also provides hosting, maintenance, and support and consulting services; and Software as a Service, including system monitoring, help desk technical support, escalation procedure development, routine diagnostic data analysis, and software updates services. The company offers its products under the PowerFleet, Pointer, and Cellocator brands. It sells its products to commercial and government sectors in manufacturing, automotive manufacturing, wholesale and retail, food and grocery distribution, pharmaceutical and medical distribution, construction, mining, utilities, heavy industry, homeland security, aerospace and defense, and vehicle rental, logistics, shipping, and freight transportation markets, as well as through indirect sales channels, such as original equipment manufacturers, vehicle importers, distributors, and industrial equipment dealers. The company was formerly known as I.D. Systems, Inc. PowerFleet, Inc. was incorporated in 1993 and is headquartered in Woodcliff Lake, New Jersey.#15 - D-Wave QuantumNYSE:QBTSStock Price: $1.19P/E Ratio: -2.24Market Cap: $202.96 millionAverage Trading Volume: 3.79 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.80 (136.3% Upside)D-Wave Quantum Inc. develops and delivers quantum computing systems, software, and services worldwide. The company offers Advantage, a fifth-generation quantum computer; Ocean, a suite of open-source python tools; and Leap, a cloud-based service that provides real-time access to a live quantum computer, as well as access to Advantage, hybrid solvers, the Ocean software development kit, live code, demos, learning resources, and a vibrant developer community. It also provides D-Wave Launch, a quantum professional service that guides enterprises from problem discovery through production implementation. The company's quantum solutions are used in logistics, financial services, drug discovery, materials sciences, scheduling, fault detection, mobility, and supply chain management. It serves financial services, manufacturing/logistics, mobility, and life sciences/pharmaceuticals industries. D-Wave Quantum Inc. was founded in 1999 and is headquartered in Burnaby, Canada.#16 - Inozyme PharmaNASDAQ:INZYStock Price: $4.40 (-$0.20)P/E Ratio: -3.21Market Cap: $272.18 millionAverage Trading Volume: 534,048 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $16.40 (272.7% Upside)Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.[Urgent] Protect your money before November (Ad)Those who listened to his warnings could have kept their money safe and even made substantial profits during each crisis. In fact, the Wall Street Journal reported that his work was more accurate … and more profitable than that of … Deutsche Bank … Merrill Lynch … JPMorgan Chase … Goldman Sachs … and every other firm reviewed.Click here to watch now.#17 - Vor BiopharmaNYSE:VORStock Price: $1.20 (+$0.03)P/E Ratio: -0.67Market Cap: $81.91 millionAverage Trading Volume: 290,089 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $12.50 (941.7% Upside)Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.#18 - Zevra TherapeuticsNASDAQ:ZVRAStock Price: $4.45 (-$0.10)P/E Ratio: -3.30Market Cap: $186.25 millionAverage Trading Volume: 229,502 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $19.50 (338.2% Upside)Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.#19 - Altus PowerNYSE:AMPSStock Price: $4.44 (+$0.17)P/E Ratio: -88.78Market Cap: $713.38 millionAverage Trading Volume: 1.13 million sharesConsensus Rating: Buy (8 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $7.50 (68.9% Upside)Altus Power, Inc., a clean electrification company, develops, owns, constructs, and operates roof, ground, and carport-based photovoltaic solar energy generation and storage systems. It serves commercial, industrial, public sector, and community solar customers. Altus Power, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.#20 - Pyxis OncologyNASDAQ:PYXSStock Price: $3.42 (-$0.24)P/E Ratio: -2.51Market Cap: $201.40 millionAverage Trading Volume: 659,652 sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.80 (157.3% Upside)Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.#21 - EnerflexNYSE:EFXTStock Price: $4.78 (-$0.05)P/E Ratio: -5.37Market Cap: $592.29 millionAverage Trading Volume: 207,317 sharesDividend Yield: 1.49%<Consensus Rating: Buy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $11.00 (130.4% Upside)Enerflex Ltd. offers energy infrastructure and energy transition solutions to natural gas markets in North America, Latin America, and the Eastern Hemisphere. The company provides natural gas compression infrastructure, processing, and treated water infrastructure under contract to oil and natural gas customers; power generation rental solutions; custom and standard compression packages for reciprocating and screw compressor applications; re-engineering, re-configuration, and re-packaging of compressors for various field applications; integrated turnkey power generation, gas compression, processing facilities, natural gas compression, processing, and electric power solutions; after-market mechanical services and parts distribution, as well as maintenance solutions to the oil and natural gas industry, operations, and overhaul services; and equipment supply, parts supply, and general asset management. It also designs, engineers, manufactures, constructs, and installs modular natural gas processing equipment, low-carbon solutions, cryogenic systems, electric power solutions, and treated water solutions; and engages in the engineering, design, procurement, project management, and construction services for compression, process, treated water, and power generation equipment, as well as after-market service, parts, and operations and maintenance services for gas compression, processing, and treated water facilities in the region. The company was formerly known as Enerflex Systems Income Fund and changed its name to Enerflex Ltd. in January 2010. Enerflex Ltd. was founded in 1980 and is headquartered in Calgary, Canada.#22 - Taboola.comNASDAQ:TBLAStock Price: $3.43 (-$0.10)P/E Ratio: -14.91Market Cap: $997.20 millionAverage Trading Volume: 1.25 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.79 (68.8% Upside)Taboola.com Ltd., together with its subsidiaries, operates an artificial intelligence-based algorithmic engine platform in Israel, the United States, the United Kingdom, Germany, and internationally. It offers Taboola, a platform that partners with websites, devices, and mobile apps to recommend editorial content and advertisements on the open web to users. The company was incorporated in 2006 and is headquartered in New York, New York.#23 - GrabNASDAQ:GRABStock Price: $3.53 (-$0.06)P/E Ratio: -50.42Market Cap: $13.85 billionAverage Trading Volume: 23.72 million sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.07 (43.7% Upside)Grab Holdings Limited engages in the provision of superapps in Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. The company offers its Grab ecosystem, a single platform with superapps for driver- and merchant-partners and consumers, that allows access to mobility, delivery, digital financial services, and enterprise sector offerings. Grab Holdings Limited is headquartered in Singapore.#24 - Tenaya TherapeuticsNASDAQ:TNYAStock Price: $3.16 (-$0.14)P/E Ratio: -1.93Market Cap: $248.12 millionAverage Trading Volume: 468,071 sharesConsensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $15.00 (374.7% Upside)Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.#25 - VerastemNASDAQ:VSTMStock Price: $3.27 (-$0.20)P/E Ratio: -0.74Market Cap: $82.83 millionAverage Trading Volume: 429,900 sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $25.69 (685.6% Upside)Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Ideas from MarketBeat Stock Lists: 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks: Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange: NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas: Wall Street Analysts are Bullish on Lyft Stock: Here's Why Buffett Bails on BYD: What It Means for the Future of EV Stocks Kraft Heinz Stock Rises as Analysts Firm Up Sentiment Domino’s vs. Papa John's: Stock Showdown of Pizza Giants Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests VinFast Auto's EV Sales Target: Stock Market Hype or Reality? Netflix Stock: Can Bundling with Competitors Drive Shares Higher? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.